The following criteria is provided for health care professionals.

Inclusion Criteria:

• Relapsed or refractory (R/R) multiple myeloma (MM) with documented evidence of progression during or after the participant's last treatment regimen.
• Measurable disease as described in the protocol.
• Received at least 1 prior line of therapy, as described in the protocol.
• Must meet prior antimyeloma treatment parameters, as described in the protocol, and includes:
• Received at least 2 consecutive cycles of lenalidomide or a lenalidomide containing regimen
• Refractory to lenalidomide
• Exposed to a proteasome inhibitor (PI) alone or in combination with another agent.
• Had a response of partial response (PR) or better to prior therapy based on the investigator's determination of response as defined by International Myeloma Working Group (IMWG) criteria.
• Has t(11;14) status as described in the protocol and meets the following criteria:
• For Part 1: MM participants independent of cytogenetic profile.
• For Part 2, Arm A: participant must be t(11;14) positive.
• For Part 2, Arm B: participant must be t(11;14) negative.
• An Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
• Adequate kidney, liver and hematologic laboratory values.

Exclusion Criteria:

• Previous treatment with venetoclax or other BCL-2 inhibitors, or previous treatment with pomalidomide
• Known sensitivity to any IMiDs
• Allogenic or syngeneic stem cell transplant within 6 months before the first dose of study drug or active ongoing graft versus host disease
• Autologous stem cell transplant within 12 weeks before the first dose of study drug
• Known meningeal involvement of MM